Updated Jan 03, 2021 | 13:22 IST The drug regulator has given a conditional nod to SII's Covishield and Bharat Biotech's Covaxin. Permission was also granted for Cadila Healthcare's Phase 3 trials. Representational Image  Drug Regulator accepts SEC's recommendations, gives conditional nod for Covishield, Covaxin PM hails the nod for SII & Bharat Biotech vaccines as a decisive turning point in fight against COVID 2021 promises to the year of vaccination in India and elsewhere Looking back, we didn’t know what was coming when 2020 descended upon us. Whi...